Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months.

Slides:

Advertisements

Similar presentations

Adjusted all-cause mortality risk by dialysate sodium (DNa) and predialysis serum sodium (SNa). Adjusted all-cause mortality risk by dialysate sodium (DNa)

Advertisements

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Differences in the glycated hemoglobin (HbA1c) levels.

Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Illustration of the causal inference scheme.

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

DASH component score by Hispanic/Latino heritage adjusted by age and sex. 1Adjusted by age and sex (mean age: 41.07, % male: 47.71). 2Each component ranges.

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Estimated HR as a function of absolute change in glycated hemoglobin (HbA1c; from index to measurement 22–26 months after). Estimated HR as a function.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Mathematical modeling of bubble formation in insulin pump cartridges (3 mL solid line, 2 mL dotted line, and 1.8 mL dashed line) and lines during an increase.

Changes over time in (A) waist circumference, (B) BMI, (C) ALT, (D) Matsuda index, (E) AUCglucagon, and (F) ISSI-2, comparing patients with drug-free diabetes.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Adjusted annual percentage of quality indicators by prescription

Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Mean and interquartile glucose values for (A) random blood glucose, (B) fastingplasma glucose, (C) HbA1c, (D) 1-hour OGTT, (E) 2-hour OGTT and (F)triglycerides.

Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients.

Age-adjusted and sex-adjusted prevalence of diabetes of Asian immigrants and whites in California from 2003 to Age-adjusted and sex-adjusted prevalence.

Association between antibiotic purchases and glycated hemoglobin (HbA1c) values in patients with and without diabetic nephropathy. Association between.

Estimated absolute incidence rates of primary TB admissions (per 10 000 total hospitalizations) by race category (Asian/Pacific Islander, Hispanic, black,

Enrollment of patients.

Hypothesized causal relations between exposures (education, immigration and income) and outcome (HbA1c at diagnosis). Hypothesized causal relations between.

Serum 25(OH)D levels stratified by the presence or absence of nephropathy. Serum 25(OH)D levels stratified by the presence or absence of nephropathy. The.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Relationships between annual antibiotic purchase rates and progression of microalbuminuria in patients with type 1 diabetes. Relationships between annual.

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Final model of factors for diabetes in the STEPwise approach to surveillance 2012 survey—Qatar among adults aged 18–64 years. Final model of factors for.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

Change in markers of glycometabolism and cardiovascular risk profile.

Interaction of updated mean serial HbA1c and serum triglyceride levels with sensory peripheral neuropathy over 7 years in 151 type 2 diabetic participants.

Participant flow diagram for the ‘GNHIES98—longitudinal sample’ and the ‘DEGS1—cross-sectional sample’. Participant flow diagram for the ‘GNHIES98—longitudinal.

Associations of body mass index (BMI) levels with achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in the upper panels.

Continuous associations

Continuous associations

Receiver-operating characteristic curves showing the performance of the diabetes risk score in predicting diabetes in the United Arab Emirates (UAE) citizens.

Categorical A1c distribution within BMI categories, n=414 266 patients with T2D and available A1c data. % values represent percentage of subjects within.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Crude and adjusted HbA1c change by medication adherence group (proportion of days covered (PDC)) by linear regression, controlling for age, age2, gender,

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Association of body mass index with all-cause mortality in diabetes and non-diabetes populations, by smoking status. Association of body mass index with.

Trends in age-adjusted diagnosed diabetes prevalence and incidence among adults aged 18–79 years, 1980–2017. Trends in age-adjusted diagnosed diabetes.

Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

Fitted seasonality for gestational diabetes mellitus (GDM) by estimated date of conception (eDoC). Fitted seasonality for gestational diabetes mellitus.

HR for mortality in ischemic heart disease.

HR for myocardial infarction.

Indirect effects of factors for diabetes in the STEPwise approach to surveillance 2012 survey—Qatar among adults aged 18–64 years. Indirect effects of.

Presentation transcript:

Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months after. Estimated HR as a function of mean residual of glycated hemoglobin (HbA1c) measurements to the line connecting index HbA1c and HbA1c measurement 22–26 months after. Analysis stratified on index HbA1c in five categories. We adjusted for age, sex (male, female), preventive pharmacological treatment of cardiovascular diseases (yes, no), prior cardiovascular disease (yes, no), number of non-cardiovascular disease, index HbA1c, and absolute change in HbA1c. The solid curves indicating adjusted estimates and dashed curves indicating 95% confidence limits. The gray spikes showing the number of people with the given mean residual (N=11 205). Mette V Skriver et al. BMJ Open Diab Res Care 2015;3:e000060 ©2015 by American Diabetes Association